Hace 12 años | Por blp a occupycorporatism.com
Publicado hace 12 años por blp a occupycorporatism.com

El Centro Internacional Fogarty de los institutos nacionales de salud (NH) de EE.UU. financió un estudio que encontró una impactante cifra, del 20 al 42% de las vacunas de la malaria utilizadas en el sudeste asiático y África subsahariana son de mala calidad o absolutamente falsas. http://cazadebunkers.wordpress.com/2012/06/04/bill-gates-la-alianza-gavi-y-la-oms-administraban-vacunas-falsas-contra-la-malaria-en-asia-india-y-africa/

Comentarios

Krisiskekrisis

Las maravillas de la "colaboración público-privada".

conversador

"Money" is "Money"

onnabancho

Por si alguien está interesado, estos son los artículos primarios.

http://www.nih.gov/news/health/may2012/fic-21.htm

In regions where malaria is prevalent, antimalarial drugs are widely distributed and self-prescribed, incorrectly or correctly. The study found there are insufficient facilities to monitor the quality of antimalarial drugs and poor consumer and health-worker knowledge about the therapies. In addition, there is a lack of regulatory oversight of manufacturing and little punitive action for counterfeiters, the paper's authors contend.

No reliable global estimates are available on the extent of poor-quality antimalarial drugs because there are no internationally accepted definitions of different types of inadequate drugs, no standard testing protocols or drug content requirements; and no recognized international forum to provide technical and scientific oversight, the study reported.




http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2812%2970064-6/abstract

Poor-quality antimalarial drugs lead to drug resistance and inadequate treatment, which pose an urgent threat to vulnerable populations and jeopardise progress and investments in combating malaria. Emergence of artemisinin resistance or tolerance in Plasmodium falciparum on the Thailand—Cambodia border makes protection of the effectiveness of the drug supply imperative. We reviewed published and unpublished studies reporting chemical analyses and assessments of packaging of antimalarial drugs. Of 1437 samples of drugs in five classes from seven countries in southeast Asia, 497 (35%) failed chemical analysis, 423 (46%) of 919 failed packaging analysis, and 450 (36%) of 1260 were classified as falsified. In 21 surveys of drugs from six classes from 21 countries in sub-Saharan Africa, 796 (35%) of 2297 failed chemical analysis, 28 (36%) of 77 failed packaging analysis, and 79 (20%) of 389 were classified as falsified. Data were insufficient to identify the frequency of substandard (products resulting from poor manufacturing) antimalarial drugs, and packaging analysis data were scarce.

Dicen que han encontrado medicamentos contra la malaria en mal estado o falsificados. No dicen que fueran administrados por la OMS. Ninguno de los artículos menciona a la OMS en ninguna parte. VOTO SENSACIONALISTA.